These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22445436)

  • 1. Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg.
    Hadji P; Biskup J; Boekhoff J; Ziller M; Bonn M; Rovati L
    Contraception; 2012 Oct; 86(4):359-65. PubMed ID: 22445436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
    Schramm G; Heckes B
    Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
    Anthuber S; Schramm GA; Heskamp ML
    Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women.
    Schramm GA; Schrah G
    Contraception; 2011 Oct; 84(4):390-401. PubMed ID: 21920195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
    Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G; Cunliffe WJ; Binder N; Höschen K
    Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea.
    Grandi G; Napolitano A; Xholli A; Tirelli A; Di Carlo C; Cagnacci A
    Gynecol Endocrinol; 2015 Oct; 31(10):774-8. PubMed ID: 26291811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.
    Pushparajah DS; Röhm P; Höschen K; Albers D; Nowack C
    Clin Drug Investig; 2011; 31(2):121-34. PubMed ID: 21155614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits.
    Heskamp ML; Schramm GA
    Contraception; 2010 Jan; 81(1):49-56. PubMed ID: 20004273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact.
    Guido M; Romualdi D; Campagna G; Ricciardi L; Bompiani A; Lanzone A
    Reprod Sci; 2010 Aug; 17(8):767-75. PubMed ID: 20595709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethinylestradiol/chlormadinone acetate.
    Curran MP; Wagstaff AJ
    Drugs; 2004; 64(7):751-60; discussion 761-2. PubMed ID: 15025547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
    Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S
    Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
    Winkler UH; Röhm P; Höschen K
    Contraception; 2010 May; 81(5):391-400. PubMed ID: 20399945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents.
    Sabatini R; Orsini G; Cagiano R; Loverro G
    Contraception; 2007 Nov; 76(5):342-7. PubMed ID: 17963857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethinylestradiol/Chlormadinone acetate: dermatological benefits.
    Guerra-Tapia A; Sancho Pérez B
    Am J Clin Dermatol; 2011 Sep; 12 Suppl 1(Suppl 1):3-11. PubMed ID: 21895044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study.
    Kerscher M; Reuther T; Bayrhammer J; Schramm G
    Clin Drug Investig; 2008; 28(11):703-11. PubMed ID: 18840013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended cycles with the combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg: pooled analysis of data from three large-scale, non-interventional, observational studies.
    Göretzlehner G; Waldmann-Rex S; Schramm GA
    Clin Drug Investig; 2011; 31(4):269-77. PubMed ID: 21250761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.